Spain In Vitro Diagnostics Market: Market Size & Forecast 2026

The in vitro diagnostics industry provides critical laboratory and point-of-care tests used across hospitals, clinical laboratories, and home care settings. Europe's IVD market, spanning Western, Central, and Southern European markets including Spain, reached approximately $32 billion in 2024 and is expected to grow to around $34 billion in 2025. Within this broader European context, Spain's molecular diagnostics segment alone represents a meaningful opportunity, valued at $305.4 million in 2025 with strong expansion ahead.

• •The pan-European IVD market is forecast to reach $57 billion by 2035, with some analyses citing a $51.82 billion value by 2034
• •Spain's molecular diagnostics sector, a key IVD sub-segment, is expected to grow from $305.4 million in 2025 to $456.2 million by 2030 at an 8.4% CAGR
• •The industry spans immunoassays, clinical chemistry, molecular diagnostics, point-of-care testing, hematology, and microbiology product categories

An aging European population and rising prevalence of chronic diseases such as diabetes and cancer are fundamental demand drivers for IVD products. The transition from the EU's previous IVD directive to the stricter IVDR regime, while creating short-term compliance burdens, is expected over time to strengthen market confidence in test quality and safety. Advances in molecular testing, next-generation sequencing, and artificial intelligence-assisted diagnostics are accelerating adoption across the region, with Spain benefiting as a hub for clinical research and biotechnology.

• •Aging demographics and growing chronic disease burdens across Spain and Europe are driving higher diagnostic testing volumes
• •EU regulatory alignment through IVDR is reshaping product approvals, favoring companies with robust clinical evidence and quality systems
• •Technological innovation in molecular diagnostics, PCR, and point-of-care platforms is expanding test capabilities and clinician adoption

Within Spain, IVD offerings span immunoassay-based tests, clinical chemistry analyzers, molecular diagnostics platforms, point-of-care rapid tests, and microbiology systems. The molecular diagnostics segment, covering infectious disease testing, genetic screening, and oncology applications, is among the fastest-growing sub-markets. Spain's position within Western Europe connects it to major supply chains, and its publicly funded National Health System remains a primary end-user of IVD products alongside private laboratory networks.

• •Spain's molecular diagnostics market: $305.4 million (2025) → $456.2 million (2030), 8.4% CAGR, covering infectious disease, genetic, and oncology tests
• •Western Europe collectively represents the largest IVD market region globally, supported by advanced healthcare infrastructure and high healthcare spending
• •The broader European IVD market is expected to grow from roughly $32 billion (2024) toward $48-57 billion by 2034-2035

What are the recent trends and outlook?

The IVD market in Spain and across Europe is moving toward more integrated, data-driven diagnostic ecosystems with connected instruments, cloud-based laboratory informatics, and AI-enabled result interpretation. Decentralized testing models, including near-patient and at-home diagnostics, are gaining momentum, particularly following lessons from the COVID-19 pandemic. Long-term, precision medicine and companion diagnostics are expected to become increasingly important as healthcare systems prioritize personalized treatment strategies.

• •Point-of-care and home-based testing devices are expected to grow faster than traditional laboratory-based IVD segments
• •Artificial intelligence and digital pathology integration are emerging as transformative technologies in diagnostic workflow optimization
• •Companion diagnostics for targeted therapies and personalized medicine represent a significant long-term growth opportunity across European markets including Spain